Repligen Corporation RGEN

Nasdaq · EDGAR · Updated Oct 31, 2026

Repligen Corporation (Nasdaq: RGEN) is a drug developer. Its lead program is at an undisclosed stage.

Upcoming catalysts

No catalyst is dated to the next 30 days or to an FDA action date.

Oct 29, 2026
n/a Repligen announced $1 billion private convertible notes transaction comprising exchange of $456.8 million principal amount of 2028 Notes for $541.4 million of new 2031 Notes and $458.6 million cash subscription.Repligen intends to use approximately $120.0 million of the net proceeds from the Subscription Transactions to repurchase shares of its common stock from certain purchasers of the New Notes through a financial intermediary at a price per share of $188.64. Filing
Oct 6, 2026
completed Repligen completed acquisition of BioLife Solutions on October 6, 2026, strengthening its position in cell therapy with a differentiated consumables platform.The completion of the BioLife acquisition in October marks a significant milestone for Repligen, and integration is progressing well. Filing

Cash runway against each catalyst, with the company's own runway statement
Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
Expected move for each dated catalyst, from comparable past events
Phase 2 evidence behind each Phase 3 readout
Companies on the same target or class
Full catalyst list with filing sentences, deals, registered trials, Excel export